Latest Advances

  • Condition: HR+/HER2- Advanced Breast Cancer (BC)
  • Journal: Annals of palliative medicine
  • Treatment Used: CDK4/6 inhibitors Combined with Endocrine Therapy
  • Number of Patients: 3685
  • Published —
This study summarized the side effects of CDK4/6 inhibitors in the treatment of patients with HR+/HER2- advanced breast cancer (BC).
  • Condition: Recurrent HER2-Negative Breast Cancer (BC)
  • Journal: International journal of clinical oncology
  • Treatment Used: Eribulin as First- or Second-Line Chemotherapy
  • Number of Patients: 58
  • Published —
This study compared the benefit of eribulin with treatment of physician's choice (TPC) as first- or second-line chemotherapy for the treatment of patients with recurrent HER2-negative breast cancer (BC).
  • Condition: HER2-Positive Metastatic Breast Cancer (mBC)
  • Journal: Breast cancer research and treatment
  • Treatment Used: Subcutaneous Trastuzumab with Pertuzumab and Docetaxel
  • Number of Patients: 276
  • Published —
This study assessed the tolerability, safety, and effectiveness of subcutaneous trastuzumab with pertuzumab and docetaxel in the treatment of patients with HER2-positive metastatic breast cancer (mBC).
  • Condition: Early-Stage Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
  • Journal: Zhonghua wai ke za zhi [Chinese journal of surgery]
  • Treatment Used: Docetaxel, Carboplatin plus Trastuzumab Regimen
  • Number of Patients: 522
  • Published —
The aim of the study was to examine the effectiveness of docetaxel, carboplatin plus trastuzumab regimen (TCH) in early-stage human epidermal growth factor receptor 2 (HER2) positive breast cancer.
  • Condition: Breast Cancer Brain Metastases
  • Journal: BMC cancer
  • Treatment Used: Trastuzumab Emtansin with Stereotactic Radiation
  • Number of Patients: 16
  • Published —
In this study, researchers evaluated the safety and effectiveness of trastuzumab emtansin with stereotactic radiation for the treatment of HER2+ breast cancer brain metastases.
  • Condition: HER2-Positive Early Breast Cancer
  • Journal: Japanese journal of clinical oncology
  • Treatment Used: Pertuzumab and Trastuzumab
  • Number of Patients: 0
  • Published —
This study evaluated the use of pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer outcomes.
  • Condition: ER+/PR+ and ER+/PR- Advanced Breast Cancer
  • Journal: Annals of palliative medicine
  • Treatment Used: First-Line Endocrine Therapy
  • Number of Patients: 225
  • Published —
This study evaluated the relationship between estrogen receptor (ER) and progesterone receptor (PR) expression status and outcomes in patients with advanced breast cancer undergoing first-line endocrine therapy.
  • Condition: Triple-Negative Breast Cancer (TNBC)
  • Journal: The Journal of international medical research
  • Treatment Used: Polymerase Inhibitors (PARPis)
  • Number of Patients: NULL
  • Published —
This study evaluated the effectiveness and safety of polymerase inhibitors (targeted therapies that are used to treat cancer; PARPis) in patients with triple-negative breast cancer (cancer cells that don’t have estrogen or progesterone receptors and also don’t make too much of the protein called HER2; TNBC).
  • Condition: Metastatic Breast Cancer
  • Journal: Cancer chemotherapy and pharmacology
  • Treatment Used: Everolimus-Exemestane
  • Number of Patients: 50
  • Published —
This study evaluated the effect of everolimus-exemestane (E/E) on CTCs in metastatic breast cancer (mBC) patients.
  • Journal: Technology in cancer research & treatment
  • Published —
Key Genes and Prognostic Analysis in HER2+ Breast Cancer.
  • Condition: Breast Cancer
  • Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • Treatment Used: Ado-Trastuzumab Emtansine (T-DM1)
  • Number of Patients: 0
  • Published —
This article discusses the use of ado-trastuzumab emtansine (T-DM1) in the treatment of patients with breast cancer.
  • Journal: Journal of cancer research and therapeutics
  • Published —
Dose-dependent cell cycle arrest and apoptosis in HER2 breast cancer cells by177Lu-CHX-A"-DTPA-Trastuzumab.
Showing 1-12 of 184